MIRM Relative Valuation
MIRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MIRM is overvalued; if below, it's undervalued.
Historical Valuation
Mirum Pharmaceuticals Inc (MIRM) is now in the Fair zone, suggesting that its current forward PS ratio of 5.69 is considered Fairly compared with the five-year average of -17.03. The fair price of Mirum Pharmaceuticals Inc (MIRM) is between 26.59 to 103.25 according to relative valuation methord.
Relative Value
Fair Zone
26.59-103.25
Current Price：51.93
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
11.01
P/B
Median3y
7.51
Median5y
6.58
-0.30
FCF Yield
Median3y
-6.65
Median5y
-11.79
Competitors Valuation Multiple
The average P/S ratio for MIRM's competitors is 5.70, providing a benchmark for relative valuation. Mirum Pharmaceuticals Inc Corp (MIRM) exhibits a P/S ratio of 5.69, which is -0.12% above the industry average. Given its robust revenue growth of 61.20%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Mirum Pharmaceuticals Inc (MIRM) currently overvalued or undervalued?
What is Mirum Pharmaceuticals Inc (MIRM) fair value?
How does MIRM's valuation metrics compare to the industry average?
What is the current P/B ratio for Mirum Pharmaceuticals Inc (MIRM) as of Jul 20 2025?
What is the current FCF Yield for Mirum Pharmaceuticals Inc (MIRM) as of Jul 20 2025?
What is the current Forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM) as of Jul 20 2025?